<p/>

Courtesy of Sigma-Aldrich

Most commercially available reagents for RNAi are synthetic oligos, which can yield good results with immortalized cell lines but are less effective in hard-to-transfect primary cells. To address this problem, The RNAi Consortium (TRC), comprising 10 biomedical research institutions, recently began the commercial rollout of its MISSION TRC shRNA library.

St. Louis-based Sigma-Aldrich http://www.sigmaaldrich.com distributes the clones in three formats: frozen bacterial glycerol stocks ($345/clone), purified plasmid DNA ($415/clone), and an active lentivirus vector (pricing not yet set). When complete, the lentiviral vector-based library will contain 150,000 shRNA constructs targeting human and mouse genes.

"The advantages of a viral system are twofold," says Keith Joliff, manager of global strategic marketing at Sigma-Aldrich. "It allows the insertion of the shRNA into the genome of the cell, so you get a permanent phenotype ... [and] it allows you to get the DNA into cell lines that do not...

Interested in reading more?

Magaizne Cover

Become a Member of

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Join for free todayAlready a member?Login Here